TransCode Therapeutics, Inc. - Common Stock (RNAZ)

U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Futures of benchmark indices were lower in premarket.

TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Let's have a look at what is happening on the US markets on Thursday. Below you can find the most active stocks in today's session.

Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

TransCode Therapeutics advances Phase 1a trial of TTX-MC138 for metastatic cancer with early signs of stability and consistent PK/PD data.

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Discover the stocks with unexpected trading volume in today's session on the US markets.

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.